Dossier
clinicaltrials
trial late
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Key claim: MANIFEST-2 is a Phase 3 randomized blinded trial comparing pelabresib plus ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naive myelofibrosis.
Abstract
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Why this matters
MANIFEST-2 is a Phase 3 randomized blinded trial comparing pelabresib plus ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naive myelofibrosis.